<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957579</url>
  </required_header>
  <id_info>
    <org_study_id>D2850C00001</org_study_id>
    <nct_id>NCT01957579</nct_id>
    <nct_alias>NCT01377116</nct_alias>
  </id_info>
  <brief_title>A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies</brief_title>
  <official_title>A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in
      Japanese patients with relapsed or refractory advanced B-cell malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2011</start_date>
  <completion_date type="Actual">September 15, 2015</completion_date>
  <primary_completion_date type="Actual">September 15, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From baseline to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities</measure>
    <time_frame>From baseline to 28 days after the first dose of study drug</time_frame>
    <description>A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>From baseline to 28 days after the first dose of study drug</time_frame>
    <description>A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)</measure>
    <time_frame>Day 0 (pre-dose)</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day84</measure>
    <time_frame>Day 84</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 112</measure>
    <time_frame>Day 112</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 140</measure>
    <time_frame>Day 140</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEDI-551 Trough Concentration Levels at Day 168</measure>
    <time_frame>Day 168</time_frame>
    <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-MEDI-551 Antibodies</measure>
    <time_frame>From baseline to 30 days after the last dose of study drug</time_frame>
    <description>Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumour Response in FL Patients</measure>
    <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
    <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumour Response in DLBCL Patients</measure>
    <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
    <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumour Response in CLL Patients</measure>
    <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
    <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008).
CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: &lt;4000/μL; Marrow: Normocellular, &lt;30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: &gt;100000/μL; Hemoglobin: &gt;11.0 g/dL; Neutrophils: &gt;1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met.
Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules.
Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: &gt;11.0 g/dL or increase ≥50% over baseline; Neutrophils: &gt;1500/μL or &gt;50% improvement over baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumour Response in MM Patients</measure>
    <time_frame>From the baseline to30 days after the last dose of study drug</time_frame>
    <description>Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006).
CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to &lt;200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Blood Cancer</condition>
  <condition>Advanced B Cell Malignancies</condition>
  <arm_group>
    <arm_group_label>MEDI-551</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle</description>
    <arm_group_label>MEDI-551</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese men or women at least 20 years of age

          -  Histologically confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL,
             or MM.

          -  Karnofsky Performance Status ≥70;

          -  Life expectancy of ≥12 weeks

        Exclusion Criteria:

          -  Any available standard line of therapy known to be life-prolonging or life-saving

          -  Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy
             for treatment of cancer

          -  Previous therapy directed against CD19, such as monoclonal antibodies or MAb
             conjugates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isehara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2013</study_first_submitted>
  <study_first_submitted_qc>October 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>February 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>advanced</keyword>
  <keyword>B cell malignancies</keyword>
  <keyword>dose escalation</keyword>
  <keyword>CD19</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled on 25 May 2011. Last patient last visit on 15 September 2015.</recruitment_details>
      <pre_assignment_details>A total of 32 patients were enrolled into the study. Twelve patients were screen failures, thus 20 patients received MEDI-551.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2 mg/kg</title>
          <description>MEDI-551 2 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>4 mg/kg</title>
          <description>MEDI-551 4 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>8 mg/kg</title>
          <description>MEDI-551 8 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>12 mg/kg</title>
          <description>MEDI-551 12 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal of concent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received at least 1 dose of MEDI-551.</population>
      <group_list>
        <group group_id="B1">
          <title>2 mg/kg</title>
          <description>MEDI-551 2mg/kg</description>
        </group>
        <group group_id="B2">
          <title>4 mg/kg</title>
          <description>MEDI-551 4 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>8 mg/kg</title>
          <description>MEDI-551 8 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>12 mg/kg</title>
          <description>MEDI-551 12 mg/kg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="8.1" lower_limit="43" upper_limit="59"/>
                    <measurement group_id="B2" value="57.4" spread="10.5" lower_limit="41" upper_limit="70"/>
                    <measurement group_id="B3" value="67.0" spread="8.7" lower_limit="54" upper_limit="72"/>
                    <measurement group_id="B4" value="67.3" spread="11.4" lower_limit="54" upper_limit="83"/>
                    <measurement group_id="B5" value="61.3" spread="11.4" lower_limit="41" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Type</title>
          <description>Disease Type (CLL: chronic lymphocytic leukemia, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MM: multiple myeloma)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CLL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLBCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>From baseline to 30 days after the last dose of study drug</time_frame>
        <population>All patients who received at least 1 dose of MEDI-551.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>All patients who received at least 1 dose of MEDI-551.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 Adverse Events (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 AE of CTCAE Grade 3 or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 Serious Adverse Events (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dose Limiting Toxicities</title>
        <description>A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.</description>
        <time_frame>From baseline to 28 days after the first dose of study drug</time_frame>
        <population>All subjects in the dose escalation phase who have received MEDI-551 at Day 1 and Day 8 and completed the safety follow-up through the dose-limiting toxicity (DLT) evaluation period (28 days), or who experienced a DLT.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities</title>
          <description>A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.</description>
          <population>All subjects in the dose escalation phase who have received MEDI-551 at Day 1 and Day 8 and completed the safety follow-up through the dose-limiting toxicity (DLT) evaluation period (28 days), or who experienced a DLT.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 Dose Limiting Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 3 or higher non-hematologic toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 3 or higher hematologic toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Tolerated Dose</title>
        <description>A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.</description>
        <time_frame>From baseline to 28 days after the first dose of study drug</time_frame>
        <population>All subjects in the dose escalation phase who have received MEDI-551 at Day 1 and Day 8 and completed the safety follow-up through the dose-limiting toxicity (DLT) evaluation period (28 days), or who experienced a DLT.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551</title>
            <description>MEDI-551 2, 4, 8 and 12 mg/kg were evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <description>A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.</description>
          <population>All subjects in the dose escalation phase who have received MEDI-551 at Day 1 and Day 8 and completed the safety follow-up through the dose-limiting toxicity (DLT) evaluation period (28 days), or who experienced a DLT.</population>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 0 (pre-dose)</time_frame>
        <population>Patients who have trough concentration data at Day 0 (pre-dose)</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 0 (pre-dose)</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Below limit of quantification</measurement>
                    <measurement group_id="O2" value="NA">Below limit of quantification</measurement>
                    <measurement group_id="O3" value="NA">Below limit of quantification</measurement>
                    <measurement group_id="O4" value="NA">Below limit of quantification</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 7</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 7</time_frame>
        <population>Patients who have trough concentration data at Day 7</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 7</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 7</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="8.65"/>
                    <measurement group_id="O2" value="39.2" spread="9.13"/>
                    <measurement group_id="O3" value="91.9" spread="31.1"/>
                    <measurement group_id="O4" value="104" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 28</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 28</time_frame>
        <population>Patients who have trough concentration data at Day 28</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 28</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 28</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="5.82"/>
                    <measurement group_id="O2" value="36.2" spread="5.34"/>
                    <measurement group_id="O3" value="103" spread="29.0"/>
                    <measurement group_id="O4" value="115" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 56</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 56</time_frame>
        <population>Patients who have trough concentration data at Day 56</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 56</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 56</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="4.92"/>
                    <measurement group_id="O2" value="33.2" spread="6.92"/>
                    <measurement group_id="O3" value="89.5" spread="13.9"/>
                    <measurement group_id="O4" value="114" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day84</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 84</time_frame>
        <population>Patients who have trough concentration data at Day 84</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day84</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 84</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="4.40"/>
                    <measurement group_id="O2" value="33.7" spread="4.24"/>
                    <measurement group_id="O3" value="91.6" spread="9.25"/>
                    <measurement group_id="O4" value="103" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 112</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 112</time_frame>
        <population>Patients who have trough concentration data at Day 112</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 112</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 112</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="3.10"/>
                    <measurement group_id="O2" value="35.3" spread="5.07"/>
                    <measurement group_id="O3" value="85.5">Standard Deviation was calculated only if n&gt;=3.</measurement>
                    <measurement group_id="O4" value="114" spread="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 140</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 140</time_frame>
        <population>Patients who have trough concentration data at Day 140</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 140</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 140</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1">Standard Deviation was calculated only if n&gt;=3.</measurement>
                    <measurement group_id="O2" value="36.3" spread="10.5"/>
                    <measurement group_id="O3" value="86.1">Standard Deviation was calculated only if n&gt;=3.</measurement>
                    <measurement group_id="O4" value="117" spread="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEDI-551 Trough Concentration Levels at Day 168</title>
        <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
        <time_frame>Day 168</time_frame>
        <population>Patients who have trough concentration data at Day 168</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>MEDI-551 Trough Concentration Levels at Day 168</title>
          <description>Lower limit of quantification for MEDI-551 was 0.1 μg/mL.</description>
          <population>Patients who have trough concentration data at Day 168</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0">Standard Deviation was calculated only if n&gt;=3.</measurement>
                    <measurement group_id="O2" value="31.4" spread="8.30"/>
                    <measurement group_id="O3" value="94.1">Standard Deviation was calculated only if n&gt;=3.</measurement>
                    <measurement group_id="O4" value="82.1">Standard Deviation was calculated only if n&gt;=3.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-MEDI-551 Antibodies</title>
        <description>Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.</description>
        <time_frame>From baseline to 30 days after the last dose of study drug</time_frame>
        <population>Patients who have at least one post-baseline sample for Anti-MEDI-551 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>MEDI-551 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>MEDI-551 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg</title>
            <description>MEDI-551 8 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg</title>
            <description>MEDI-551 12 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-MEDI-551 Antibodies</title>
          <description>Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.</description>
          <population>Patients who have at least one post-baseline sample for Anti-MEDI-551 antibodies.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>positive at least 1 time point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>negative at all time points</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumour Response in FL Patients</title>
        <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
        <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
        <population>All patients with FL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg (FL)</title>
            <description>FL patients in MEDI-551 2 mg/kg cohort</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg (FL)</title>
            <description>FL patients in MEDI-551 4 mg/kg cohort</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg (FL)</title>
            <description>FL patients in MEDI-551 8 mg/kg cohort</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg (FL)</title>
            <description>FL patients in MEDI-551 12 mg/kg cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumour Response in FL Patients</title>
          <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
          <population>All patients with FL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumour Response in DLBCL Patients</title>
        <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
        <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
        <population>All patients with DLBCL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg (DLBCL)</title>
            <description>DLBCL patients in MEDI-551 2 mg/kg cohort</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg (DLBCL)</title>
            <description>DLBCL patients in MEDI-551 4 mg/kg cohort</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg (DLBCL)</title>
            <description>DLBCL patients in MEDI-551 8 mg/kg cohort</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg (DLBCL)</title>
            <description>DLBCL patients in MEDI-551 12 mg/kg cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumour Response in DLBCL Patients</title>
          <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007).
CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.</description>
          <population>All patients with DLBCL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumour Response in CLL Patients</title>
        <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008).
CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: &lt;4000/μL; Marrow: Normocellular, &lt;30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: &gt;100000/μL; Hemoglobin: &gt;11.0 g/dL; Neutrophils: &gt;1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met.
Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules.
Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: &gt;11.0 g/dL or increase ≥50% over baseline; Neutrophils: &gt;1500/μL or &gt;50% improvement over baseline.</description>
        <time_frame>From the baseline to 30 days after the last dose of study drug</time_frame>
        <population>All patients with CLL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg (CLL)</title>
            <description>CLL patients in MEDI-551 2 mg/kg cohort</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg (CLL)</title>
            <description>CLL patients in MEDI-551 4 mg/kg cohort</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg (CLL)</title>
            <description>CLL patients in MEDI-551 8 mg/kg cohort</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg (CLL)</title>
            <description>CLL patients in MEDI-551 12 mg/kg cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumour Response in CLL Patients</title>
          <description>Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008).
CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: &lt;4000/μL; Marrow: Normocellular, &lt;30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: &gt;100000/μL; Hemoglobin: &gt;11.0 g/dL; Neutrophils: &gt;1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met.
Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules.
Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: &gt;11.0 g/dL or increase ≥50% over baseline; Neutrophils: &gt;1500/μL or &gt;50% improvement over baseline.</description>
          <population>All patients with CLL who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumour Response in MM Patients</title>
        <description>Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006).
CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to &lt;200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.</description>
        <time_frame>From the baseline to30 days after the last dose of study drug</time_frame>
        <population>All patients with MM who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg (MM)</title>
            <description>MM patients in MEDI-551 2 mg/kg cohort</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg (MM)</title>
            <description>MM patients in MEDI-551 4 mg/kg cohort</description>
          </group>
          <group group_id="O3">
            <title>8 mg/kg (MM)</title>
            <description>MM patients in MEDI-551 8 mg/kg cohort</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg (MM)</title>
            <description>MM patients in MEDI-551 12 mg/kg cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumour Response in MM Patients</title>
          <description>Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006).
CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to &lt;200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.</description>
          <population>All patients with MM who received at least 1 dose of MEDI-551 and completed at least 1 post-baseline disease assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected throughout the study, from informed consent until the end of 30 days after study treatment. The follow-up period is defined as 3 months after study treatment is discontinued.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 mg/kg</title>
          <description>MEDI-551 2mg/kg</description>
        </group>
        <group group_id="E2">
          <title>4 mg/kg</title>
          <description>MEDI-551 4 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>8 mg/kg</title>
          <description>MEDI-551 8 mg/kg</description>
        </group>
        <group group_id="E4">
          <title>12 mg/kg</title>
          <description>MEDI-551 12 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sebaceous adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>MedImmune, LLC</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

